David Thomas is a public figure in current affairs; recently profiled amid Barratt Redrow share buyback moves and discussions on health research headlines.
Barratt Redrow has announced investor returns plans, returning about £400 million via buybacks and £14 million via dividends, while signaling continued cost-cutting and supply chain management to offset higher build costs. The update follows investor pressure from Phoenix Asset Management Partners to pursue larger buybacks.